SEO URLwww.firestrike.ai/deals/candid-therapeutics-rallybio-acquisition-2026
acquisitionAnnounced · Mar 3, 2026BiotechnologySource · CredibleArticle · Factual
Rallybio acquires Candid Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$505M
Target
Candid Therapeutics
Nasdaq:CDRX
Acquirer
Rallybio
Merger
Status
Pending
Rallybio agreed to acquire Candid Therapeutics. Reported deal value: $505M. Status: Pending. Sector: Biotechnology. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-03-03. Figures and status may change as filings and press coverage update.
Rallybio to acquire Candid Therapeutics Salong Debbarma Tue, March 3, 2026 at 1:29 PM GMT+1 2 min read RLYB US- based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction
Deal timeline
Announced
Mar 3, 2026 · finance.yahoo.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology with a reported deal value of $505M. Figures and status may change as sources update.
Sources: finance.yahoo.com · Primary article · FireStrike proprietary index